Related Experiment Video
Updated: May 20, 2026
Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
Published on: August 16, 2024
Engineered Extracellular Vesicles in Glioma Therapy: Recent Advances and Applications
Linjin Xiong1, Xintian Yu1, Tao Chen2
1Department of Pharmacy, Hi-Tech Zone Hospital for Women and Children, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.
Abstract:
Gliomas are a highly heterogeneous group of primary tumors of the central nervous system. The blood-brain barrier and the complex tumor microenvironment restrict drug penetration and reduce the effectiveness of standard chemotherapy. Extracellular vesicles (EVs) have gained attention as potential delivery vehicles because they can move across biological barriers, are generally well tolerated, and naturally shuttle signals between cells. However, unmodified EVs face practical hurdles for clinical use, including limited tissue targeting, modest drug payload capacity, low manufacturing yield, and imperfect control over what they carry. To overcome these constraints, growing efforts have focused on engineering EVs to improve delivery performance and therapeutic precision. This review outlines key EV characteristics and commonly used isolation methods, with an emphasis on engineering approaches for glioma therapy. We also summarize recent progress in engineered EV-based treatments for glioma and discuss the main barriers to clinical translation.
Insights
Engineered extracellular vesicles (EVs) show promise for overcoming challenges in glioma treatment by improving drug delivery across the blood-brain barrier. Further research is needed to address limitations for clinical translation.
Area of Science:
- Neuro-oncology
- Biotechnology
- Drug Delivery Systems
Background:
- Gliomas are complex central nervous system tumors with a challenging microenvironment that limits chemotherapy efficacy.
- The blood-brain barrier restricts drug penetration, necessitating novel therapeutic strategies.
- Extracellular vesicles (EVs) are natural carriers with potential for drug delivery but require modification for clinical application.
Purpose of the Study:
- To review extracellular vesicle (EV) characteristics and isolation methods.
- To highlight engineering strategies for enhancing EV-based glioma therapy.
- To summarize progress and challenges in translating engineered EVs for clinical use.
Main Methods:
- Review of existing literature on EV biology, engineering, and applications in glioma.
- Analysis of EV isolation techniques and their suitability for therapeutic development.
- Examination of engineering approaches to improve EV targeting, payload, and production.
Main Results:
- Engineered EVs offer improved tissue targeting, drug payload capacity, and controlled cargo compared to unmodified EVs.
- Recent advancements demonstrate the potential of engineered EVs in preclinical glioma models.
- Key challenges remain in manufacturing yield, scalability, and clinical validation.
Conclusions:
- Engineered extracellular vesicles represent a promising platform for advanced glioma therapy.
- Overcoming current limitations in EV engineering and manufacturing is crucial for clinical translation.
- Further research and development are essential to realize the full therapeutic potential of engineered EVs in neuro-oncology.
More Related Videos
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
10:09Characterization of Immune Cell-derived Extracellular Vesicles and Studying Functional Impact on Cell Environment
Published on: June 2, 2020